VisCardia

VisCardia is a clinical-stage medical device company targeting the massive and growing heart failure market with its novel SDS® therapy. The technology involves implantable stimulation of the diaphragm to improve ventricular function, offering a potential alternative for patients inadequately managed by drugs but not candidates for complex surgeries. Having completed initial European clinical studies, the company is positioning its data for presentation at major cardiology conferences as it advances toward later-stage development and potential commercialization.

Synchronized Diaphragmatic Stimulation (SDS®): An implantable neurostimulation device that delivers timed electrical pulses to the diaphragm to mechanically improve ventricular filling and cardiac function.

Competes indirectly with pharmaceutical heart failure regimens and directly with cardiac resynchronization therapy (CRT) devices. For advanced patients, it would compete with more invasive surgical options like ventricular assist devices (VADs) and transplants. It may also face future competition from other novel device-based approaches for heart failure.